Barbara Leyman is currently SVP, Corporate Development at GenEdit is an experienced biotech leader (19+ years) in business development, alliance management and corporate strategy. Barbara is trained as a scientist by training with a PhD from Imperial College, London University (UK) and is an executive master in entrepreneurship and innovation (Vlerick, Belgium). She holds a strong track record of deal making (buy and sell side) in various backgrounds and companies such as VIB and LRM in Belgium, Europe and Calicolabs, Lyell Immunopharma and GenEdit in CA (Bay Area), US. She has experience with different types of deals such as R&D collaborations, licensing (in and out) as well as investment private equity deals. Barbara was a board director at Amakem, Complix and Apitope. Recently Barbara led the transaction executed between GenEdit and Genentech as announced in January 2024, a multiyear collaboration and license agreement with a potential total of $644M payment in milestones to GenEdit.